
Stefan Hatzl

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/605831/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel. Thrombosis and Haemostasis, 2022, 122, 633-645.	3.4	7
2	Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European Confederation of Medical Mycology. Clinical Microbiology and Infection, 2022, 28, 580-587.	6.0	133
3	Early Treatment with Sotrovimab for Covid-19. New England Journal of Medicine, 2022, , .	27.0	1
4	Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation. Journal of Antimicrobial Chemotherapy, 2022, 77, 2500-2505.	3.0	17
5	Autopsy Proven Pulmonary Mucormycosis Due to Rhizopus microsporus in a Critically III COVID-19 Patient with Underlying Hematological Malignancy. Journal of Fungi (Basel, Switzerland), 2021, 7, 88.	3.5	79
6	Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia. Clinical Epigenetics, 2021, 13, 1.	4.1	57
7	Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy. Supportive Care in Cancer, 2021, 29, 5197-5207.	2.2	6
8	EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity. Leukemia, 2021, 35, 1521-1526.	7.2	3
9	Convalescent plasma therapy and mortality in COVID-19 patients admitted to the ICU: a prospective observational study. Annals of Intensive Care, 2021, 11, 73.	4.6	9
10	miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms. Annals of Hematology, 2021, 100, 2845-2847.	1.8	1
11	Prognostic Value of Baseline and Interim Positron Emission Tomography Markers in Diffuse Large B-cell Lymphoma Patients: A Real-world Perspective. HemaSphere, 2021, 5, e621.	2.7	0
12	Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study. Critical Care, 2021, 25, 335.	5.8	61
13	Soluble urokinase plasminogen activator receptor (suPAR) predicts critical illness and kidney failure in patients admitted to the intensive care unit. Scientific Reports, 2021, 11, 17476.	3.3	8
14	Antibiotic use and ileocolonic immune cells in patients receiving fecal microbiota transplantation for refractory intestinal GvHD: a prospective cohort study. Therapeutic Advances in Hematology, 2021, 12, 204062072110583.	2.5	9
15	CD19+lgD+CD27- NaÃ ⁻ ve B Cells as Predictors of Humoral Response to COVID 19 mRNA Vaccination in Immunocompromised Patients. Frontiers in Immunology, 2021, 12, 803742.	4.8	27
16	Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis. Haematologica, 2020, 105, 375-386.	3.5	11
17	The role of germline mutation profiling in the selection of related donors for haematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 1502-1505.	2.4	3
18	Heparins as cancer therapy: in theory, they should have worked. Lancet Haematology,the, 2020, 7, e703-e704.	4.6	0

STEFAN HATZL

#	Article	IF	CITATIONS
19	Response to "COVID-19 in persons with haematological cancersâ€: Leukemia, 2020, 34, 2265-2270.	7.2	19
20	The Role of Immunohistochemical Overexpression of p53 as Adverse Prognostic Factor in Primary Testicular Diffuse Large B Cell Lymphoma. Pathology and Oncology Research, 2020, 26, 2831-2833.	1.9	2
21	Increased Expression of Micro-RNA-23a Mediates Chemoresistance to Cytarabine in Acute Myeloid Leukemia. Cancers, 2020, 12, 496.	3.7	12
22	Immunohistochemistry for câ€myc and bclâ€2 overexpression improves risk stratification in primary central nervous system lymphoma. Hematological Oncology, 2020, 38, 277-283.	1.7	19
23	AÂwearable cardioverter defibrillator for prevention of sudden cardiac death in aÂhematologic patient—aÂcase report. Memo - Magazine of European Medical Oncology, 2019, 12, 269-271.	0.5	0
24	NR4A3 Suppresses Lymphomagenesis through Induction of Proapoptotic Genes. Cancer Research, 2017, 77, 2375-2386.	0.9	24
25	Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs. International Journal of Molecular Sciences, 2016, 17, 2080.	4.1	58
26	Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP. Cancer Research, 2016, 76, 3644-3654.	0.9	45
27	Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation. PLoS ONE, 2015, 10, e0129859.	2.5	8
28	Deletion of SPRY4 is a frequent event in secondary acute myeloid leukemia. Annals of Hematology, 2015, 94, 1923-1924.	1.8	5